Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA4 | P43681 | 4/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.47 |
| ▸ | CSF1R | P07333 | 11/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.36 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | F2 | P00734 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2910035 | 0.80 | CHRNA4 (0.51) | CHRNA4CHRNB2CHRNB4CHRNA3CSF1R | |
| SCHEMBL9373067 | 0.78 | CHRNB2 (0.46) | CHRNA4CHRNB2CHRNB4CHRNA3CSF1R | |
| SCHEMBL16131795 | 0.78 | CHRNB2 (0.46) | CHRNA4CHRNB2CHRNB4CHRNA3CSF1R | |
| SCHEMBL1355720 | 0.78 | MAPT (0.39) | CES1ALDH1A1 | |
| SCHEMBL9372891 | 0.75 | CHRNA4 (0.44) | CHRNA4CHRNB2CHRNB4CHRNA3CSF1R | |
| SCHEMBL6443012 | 0.74 | CHRNB2 (0.43) | CHRNA4CHRNB2CHRNB4CHRNA3CSF1R | |
| SCHEMBL9371766 | 0.74 | GSK3B (0.47) | CHRNA4CHRNB2CHRNB4CHRNA3CSF1R | |
| SCHEMBL6444899 | 0.74 | ALDH1A1 (0.61) | CHRNA4CHRNB2CHRNB4CHRNA3CSF1R | |
| SCHEMBL3323814 | 0.74 | KDM4E (0.65) | CHRNA4KDM4EALDH1A1LMNAL3MBTL1 | |
| SCHEMBL1993729 | 0.72 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104140421-B | Benzo isothiazole compound and the application in antipsychotic drug is prepared | 上海医药工业研究院 | 2017-04-05 | — | — | CN | disclosed |
| US-9526731-B2 | Method of inhibiting C-KIT kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-12-27 | — | — | US | disclosed |
| EP-1807077-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-23 | — | — | EP | disclosed |
| US-9452996-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2016-09-27 | — | — | US | disclosed |
| EP-2021329-B1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-13 | — | — | EP | disclosed |
| US-20160046602-A1 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-18 | — | — | US | disclosed |
| US-9221797-B2 | Inhibitors of c-fms kinase | JANSSEN PHARMACEUTICA NV (BE) | 2015-12-29 | — | — | US | disclosed |
| CN-102670605-B | Suppress the kinase whose method of C KIT | JANSSEN PHARMACEUTICA N. V. (BE) | 2015-07-29 | — | — | CN | disclosed |
| US-20150094520-A1 | METHOD OF INHIBITING C-KIT KINASE | JANSSEN PHARMACEUTICA NV (BE) | 2015-04-02 | — | — | US | disclosed |
| US-8933091-B2 | Method of inhibiting C-KIT kinase | JANSSEN PHARMACEUTICA NV (BE) | 2015-01-13 | — | — | US | disclosed |
| WO-2006047277-A2 | INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-04 | — | — | WO | disclosed |
| WO-2006047504-A1 | AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-04 | — | — | WO | disclosed |
| WO-2006047479-A2 | C-FMS KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-05-04 | — | — | WO | disclosed |
| EP-1631560-A2 | C-FMS KINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20050131022-A1 | C-fms kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-06-16 | — | — | US | disclosed |
| US-20050004112-A1 | C-fms kinase inhibitors | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
| WO-2004096795-A2 | C-FMS KINASE INHIBITORS | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| EP-0118790-B1 | NOVEL AROYLIMIDAZOLONES | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-07-06 | — | — | EP | disclosed |
| US-4552880-A | Aroylimidazolones | MERRELL DOW PHARMACEUTICALS INC. (US) | 1985-11-12 | — | — | US | disclosed |
| EP-0118790-A1 | Novel aroylimidazolones | MERRELL DOW PHARMACEUTICALS INC. (US) | 1984-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131022-A1 | C-fms kinase inhibitors | FLT3, FES, FGR | CHRNA4 4343/4885CHRNB2 4463/4885CHRNB4 4315/4885 |
| US-20050004112-A1 | C-fms kinase inhibitors | FLT3, FGR, FER | CHRNA4 4296/4885CHRNB2 4308/4885CHRNB4 4219/4885 |
| US-20160046602-A1 | INHIBITORS OF C-FMS KINASE | FES, MUSK, FRK | CHRNA4 2171/4885CHRNB2 1934/4885CHRNB4 2170/4885 |
| US-20150094520-A1 | METHOD OF INHIBITING C-KIT KINASE | KIT, CHUK, MAP3K13 | CHRNA4 2651/4885CHRNB2 2455/4885CHRNB4 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.